BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200123
DTEND;VALUE=DATE:20200125
DTSTAMP:20200105T182855Z
CREATED:20191205T175457Z
LAST-MODIFIED:20200105T182855Z
UID:36104-1579737600-1579910399@globalbiodefense.com
SUMMARY:National Science Advisory Board for Biosecurity (NSABB) Meeting
DESCRIPTION:The National Science Advisory Board for Biosecurity (NSABB) will convene 23-24 January 2020 in Bethesda\, Md. \nThe meeting will be open to the public\, with attendance limited to space available. The meeting will also be videocast. \nJanuary 23: 12:30 PM – 5 PM Eastern\nJanuary 24: 9 AM – 2:30 PM Eastern \nThe purpose of this meeting is to discuss considerations regarding security and public transparency when sharing information about research involving enhanced potential pandemic pathogens; as well as other business of the Board. \nIf you plan to attend the meeting in person please pre-register HERE.\nIndividuals in attendance may also register onsite on the day of the meeting.\nDraft Agenda will be posted when available. \nVideocasts: \n\nDay 1 – Link will be available on January 23\, 2020\nDay 2 – Link will be available on January 24\, 2020\n\nPlease visit the website for more information: http://bit.ly/NSABB-Meetings \nCurrent Voting Board Members\nMargie D. Lee\, DVM\, PhD*\nProfessor and Head\, Department of Biomedical Sciences and Pathobiology\nVirginia-Maryland College of Veterinary Medicine\nVirginia Tech \nStephen S. Morse\, PhD*\nDirector\, Infectious Disease Epidemiology Certificate Program\nProfessor of Epidemiology\nMailman School of Public Health\nColumbia University \nJean L. Patterson\, PhD\nProfessor\, Virology and Immunology Chair\, BSL-4 Task Force\nTexas Biomedical Research Institute \nRozanne M. Sandri-Goldin\, PhD\nProfessor and Chair\, Department of Microbiology and\nMolecular Genetics\nUniversity of California Irvine School of Medicine \nKenneth Bernard\, MD\nRADM\, U.S. Public Health Service (Ret.)\nFormer Special Assistant to the President for Biodefense\, Homeland Security Council\, White House\nFormer Special Adviser for Health and Security on the National Security Council \nCraig E. Cameron\, PhD\nJeffrey Houpt Distinguished Investigator\nChair\, Department of Microbiology and Immunology\nUniversity of North Carolina Chapel Hill School of Medicine \nMark Denison\, MD\nProfessor and Chair of Pediatrics\nAssociate Professor of Microbiology and Immunology\nVanderbilt University School of Medicine \nJohn D. Grabenstein\, RPh\, PhD\nSenior Medical Director\, Adult Vaccines\nMerck Vaccine Division\nMerck & Co.\, Inc. \nMarie-Louise Hammarskjöld\, MD\, PhD\nCharles H. Ross Jr. Professor and Professor of Microbiology\, Immunology\, and Cancer Biology\nAssociate Director\, Myles H. Thaler Center\nUniversity of Virginia School of Medicine \nJames W. LeDuc\, PhD\nDirector\, Galveston National Laboratory\nProfessor\, Department of Microbiology and Immunology\nUniversity of Texas Medical Branch
URL:https://globalbiodefense.com/event/national-science-advisory-board-for-biosecurity-nsabb-meeting/
LOCATION:Hyatt Regency Bethesda\, One Bethesda Metro Center\, Bethesda\, MD\, 20814\, United States
CATEGORIES:Conference,Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T110000
DTEND;TZID=America/New_York:20200126T140000
DTSTAMP:20201127T192409Z
CREATED:20201127T192409Z
LAST-MODIFIED:20201127T192409Z
UID:48057-1580036400-1580047200@globalbiodefense.com
SUMMARY:Envisioning a Transformed Clinical Trials Enterprise for 2030
DESCRIPTION:The National Academies’ Forum on Drug Discovery\, Development\, and Translation will host a virtual public workshop on Jan 26\, 2021 as part of a web series forum of events to discuss critical policy for advancement of biopharmaceutical innovation nationally and globally. \nThis virtual public workshop will provide a venue for stakeholders to consider a transformed clinical trial enterprise for 2030. Workshop participants will consider lessons learned from progress and setbacks over the past 10 years\, since the previous workshop\, Envisioning a Transformed Clinical Trials Enterprise in the United States\, and\, looking forward\, discuss goals and key priorities for advancing a clinical trials enterprise that is more efficient\, effective\, person-centered\, inclusive\, and integrated into the health delivery system of 2030. \nThe event will provide an overview discussion on how an envisioned 2030 clinical trials enterprise may differ from the current system. It will discuss key challenges and opportunities in improving person-centeredness and inclusivity\, building resilience and transparency\, and integrating new technologies. \nThe workshop session will consider changes in the clinical trials enterprise made in response to COVID-19 that may establish positive and sustainable examples for the future\, and consider specific action steps that individual stakeholders could take to support an envisioned change from 2020 to 2030. \nFor additional information on the workshop series\, please visit the project page. \nBackground\nClinical trials research has changed dramatically over the last decade. The biological\, physical\, and digital spheres are merging; clinical research and health care are at a critical juncture; new approaches enable the collection of data in real-world settings; and new modalities\, such as digital health technologies and artificial intelligence applications\, are changing possibilities for the conduct of clinical research. These opportunities hold great promise for advancing our understanding of health maintenance and prevention\, disease progression\, and developing new therapies for patients. At the same time\, the clinical research enterprise is strained by rising costs\, an evolving regulatory and economic landscape\, increasing clinical trial complexity\, difficulties in the recruitment and retention of research participants\, and a clinical research workforce that is under tremendous stress. Some\, but not all\, of these challenges and opportunities were predicted in the 2011 National Academies workshop\, Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020. There is now a need for stakeholders from across the clinical research lifecycle to consider lessons learned from progress and setbacks over the past 10 years and broadly consider goals and key priorities for advancing a clinical trials enterprise that is more efficient\, effective\, person-centered\, inclusive\, and integrated into the health delivery system of 2030.
URL:https://globalbiodefense.com/event/envisioning-a-transformed-clinical-trials-enterprise-for-2030/
CATEGORIES:Webinar-Webcast,Workshop
LOCATION:https://bit.ly/nasem-clinicaltrialenterprise
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200127T140000
DTEND;TZID=America/New_York:20200127T150000
DTSTAMP:20200126T224608Z
CREATED:20200124T185703Z
LAST-MODIFIED:20200126T224608Z
UID:37773-1580133600-1580137200@globalbiodefense.com
SUMMARY:CDC National Call Series on Novel Coronavirus Monitoring & Preparedness
DESCRIPTION:The Centers for Disease Control and Prevention (CDC) is closely monitoring an outbreak caused by a novel (new) coronavirus in Wuhan City\, Hubei Province\, China. A number of countries\, including the U.S.\, are actively screening incoming travelers from Wuhan. \nStarting January 21\, 2020\, CDC’s 2019 Novel Coronavirus (2019-nCoV) response team will host a series of national calls to continue providing state and local partners with the latest information on the novel coronavirus outbreak and U.S. preparedness efforts. \nThe call schedule is currently set as follows: \n\n21 January 2:00-3:00pm EST\n27 January 2:00-3:00pm EST\n3 February 2:00-3:00pm EST\n10 February 2:00-3:00pm EST\n24 February 2:00-3:00pm EST\n2 March 2:00-3:00pm EST\n\n  \nParticipant Information \nBridgeline: \n1(800)-857-6697 Participant \nPasscode: 1324420 \nIf you have any questions about the call series\, please contact the CDC State Coordination Task Force (SCTF) – Operations. \n(h/t NACCHO for originally posting this information.)
URL:https://globalbiodefense.com/event/cdc-national-call-series-on-novel-coronavirus-monitoring-preparedness/
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200128
DTEND;VALUE=DATE:20200130
DTSTAMP:20191227T191045Z
CREATED:20191127T185911Z
LAST-MODIFIED:20191227T191045Z
UID:36001-1580169600-1580342399@globalbiodefense.com
SUMMARY:Tick-Borne Disease Working Group (TBDWG)
DESCRIPTION:The 11th meeting of the Tick-borne Disease Working Group (TBDWG) will be held on January 28 and 29\, 2020\, from 9:00 a.m. to 4:30 p.m. ET on both days (times subject to change). \nThe meeting will be held at the in Washington D.C. and by webcast. Preregistration for public members is advisable and can be accomplished by registering here. \nThe TBDWG was established by Congress in 2016 as part of the 21st Century Cures Act to provide subject matter expertise and to review federal efforts related to all tick-borne diseases\, to help ensure interagency coordination and minimize overlap\, and to examine research priorities.  The focus of this effort is the development of a report to the Secretary of Health and Human Services and Congress on the findings and any recommendations of the Working Group for the federal response to tick-borne disease prevention\, treatment and research\, as well as how to address gaps in these areas. \nFor this meeting\, the Working Group will hear presentations from eight subcommittees on their findings and potential actions for the TBDWG to consider; hear updates from the Public Comment and Inventory Subcommittees; and further discuss plans for developing the 2020 report to the HHS Secretary and Congress on federal tick-borne activities and research. \nPublic Comment – Information and Instructions\nThe public will have an opportunity to present their views to the Working Group during the meeting’s public comment session or by submitting their views in writing. \nVerbal comments (in-person): \n\nRequests to provide verbal public comment must be submitted via email by midnight Tuesday\, January 17\, 2020\, ET to tickbornedisease@hhs.gov. In the Subject line please enter: Verbal Public Comment – January 28-29 Meeting. In addition\, please indicate if you will be providing verbal comment in person or by phone. If by phone\, you will be provided a call-in number and and time to call.\nA total of 30 minutes has been set aside for verbal comments on both days. Each person will be limited to 3 minutes in order to accommodate as many speakers as possible. If more requests are received than can be accommodated\, speakers will be randomly selected.\nYour remarks will be heard over a live webcast and will become part of the archived recording and meeting summary that will be posted on this website.\n\nWritten comments \n\nWritten public comments must be submitted via email by midnight Tuesday\, January 17\, 2020\, ET to tickbornedisease@hhs.gov. In the Subject line please enter: Written Public Comment – January 28-29 Meeting.\nWhen you submit your written comment\, please include a statement letting the TBDWG know how you would like to be identified with your comment. You may choose to use your name or to be anonymous. You may also list your city and/or state. If you are providing comments on behalf of an organization\, please include the name of the organization. TBDWG cannot post your comment until you let us know how you would like to be identified.\nComments should either be provided in the body of your email\, or in an attachment in Word format and equivalent to no more than 4 pages in Calibri or Times New Roman\, 11 point font. Text that exceeds the 4 pages will be deleted.\nTBDWG will not post graphics\, images\, text boxes\, or tables. If included with your comment\, they will not be able to retain them.\nTBDWG can only create hyperlinks to “.gov” sites (local\, state\, or federal). For all other reference sites\, please insert the full URL (e.g.\, http://learn.genetics.utah.edu/content/epigenetics).\nTBDWG is also unable to include attachments as supporting documentation to your written comments.\n\n\n\n\nAgenda\nDraft agenda – subject to change. \nDay 1 – January 28\, 2020 \n\n\n\nTime\nAgenda Item\nSpeaker\n\n\n\n\n9:00 am – 9:05 am\n– Welcome from the Working Group\n– Roll Call: During roll call members are asked to state their organization and what subcommittee(s) they co-chair\nLeigh Ann Soltysiak\, Co-Chair\nDavid Walker\, Co-Chair\nJim Berger\, DFO\n\n\n9:05 am – 9:07 am\nOverview of the Working Group’s Mission\, Vision Statement\, Values\nJim Berger\, DFO\n\n\n9:07 am – 9:10 am\n– Update from September 12\, 2019\, Meeting to Today\n– Review 2020 TBDWG objectives\n– What We Hope to Accomplish Today\n– Introduction of Speakers\nLeigh Ann Soltysiak\, Co-Chair\nDavid Walker\, Co-Chair\n\n\n9:15 am – 9:20 am\n– NIH Strategic Plan Update\n– CDC-led Domestic Framework\nSam Perdue\nBen Beard\n\n\n9:20 am – 9:50 am\nPublic Comments\n–\n\n\n9:50 am – 10:00 am\nPublic Comment Subcommittee Update\n– Comments received\n– Overall themes\nScott Commins\, Co-Chair\nAngel Davey\, Co-Chair\nLeigh Ann Soltysiak\, Co-Chair\n\n\n10:00 am – 11:00 am\nSubcommittee Presentation – Tick Biology\, Ecology\, and Control Subcommittee\nKevin Macaluso\, Co-Chair\nBeto Perez de Leon\, Co-Chair\n\n\n11:00 am – 11:15 am\nBreak\n–\n\n\n11:15 am – 12:15 pm\nSubcommittee Presentation – Pathogenesis and Physiology of Lyme Disease Subcommittee\nSam Donta\, Co-Chair\nLeith States\, Co-Chair\n\n\n12:15 pm – 1:15 pm\nSubcommittee Presentation – Clinical Aspects of Lyme Disease Subcommittee\nCDR Rebecca Bunnell\, Co-Chair\nSam Donta\, Co-Chair\n\n\n1:15 pm – 2:15 pm\nLunch\n–\n\n\n2:15 pm – 3:15 pm\nSubcommittee Presentation – Training\, Education\, Access to Care\, and Reimbursement Subcommittee\nCDR Rebecca Bunnell\, Co-Chair\nPat Smith\, Co-Chair\n\n\n3:15 pm – 4:15 pm\nSubcommittee Presentation – Alpha-gal Subcommittee\nScott Commins\, Co-Chair\nAngel Davey\, Co-Chair\nLeigh Ann Soltysiak\, Co-Chair\n\n\n4:15 pm\nAdjourn\n–\n\n\n\nDay 2 – January 29\, 2020 \n\n\n\nTime\nAgenda Item\nSpeaker\n\n\n\n\n9:00 am – 9:05 am\nWelcome from the Working Group\nLeigh Ann Soltysiak\, Co-Chair\nDavid Walker\, Co-Chair\n\n\n9:05 am – 9:07 am\nRecap of First Day\nJim Berger\, DFO\n\n\n9:07 am – 9:37 am\nPublic Comments\n–\n\n\n9:37 am – 10:37 am\nSubcommittee Presentation – Babesiosis and Tick-Borne Pathogens Subcommittee\nBen Beard\, Co-Chair\nGene Shapiro\, Co-Chair\n\n\n10:37 am – 10:52 am\nBreak\n–\n\n\n10:52 am – 11:52 am\nSubcommittee Presentation – Ehrlichiosis and Anaplasmosis Subcommittee\nDennis Dixon\, Co-Chair\nDavid Walker\, Co-Chair\n\n\n11:52 am – 12:52 pm\nSubcommittee Presentation – Rickettsiosis Subcommittee\nEstella Jones\, Co-Chair\nDavid Walker\, Co-Chair\n\n\n12:52 pm – 1:52 pm\nLunch\n–\n\n\n1:52 pm – 1:57 pm\nFederal Inventory Update\n– What has been received\n– What is outstanding\nJim Berger\, DFO\n\n\n1:57 pm – 3:07 pm\nOpen Discussions for Working Group\nWorking Group\n\n\n3:07 pm – 3:22 pm\nBreak\n–\n\n\n3:22 pm – 3:52 pm\nDiscussion of Next Steps and What is Expected for the March Meeting\nLeigh Ann Soltysiak\, Co-Chair\nDavid Walker\, Co-Chair\n\n\n3:52 pm – 3:57 pm\nReview Draft Outline of Report to Congress\nWorking Group\n\n\n3:57 pm – 4:30 pm\nOpen Discussion for Working Group\nWorking Group\n\n\n4:30 pm\nAdjourn\n–\n\n\n\nPlease view the Federal Register Meeting Notice and visit the meeting page for the latest information. \n 
URL:https://globalbiodefense.com/event/tick-borne-disease-working-group-tbdwg/
LOCATION:Hyatt Place Washington DC/US Capitol\, 33 New York Avenue\, Washington\, DC\, 20002\, United States
CATEGORIES:Policy-Legislative,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2014/05/tick_amber_ancient_lyme.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200131T140000
DTEND;TZID=America/New_York:20200131T150000
DTSTAMP:20200131T163844Z
CREATED:20200131T143313Z
LAST-MODIFIED:20200131T163844Z
UID:37932-1580479200-1580482800@globalbiodefense.com
SUMMARY:CDC COCA Call: Outbreak of 2019-nCoV: Interim Guidance for Clinicians
DESCRIPTION:The CDC will hold a COCA (Clinicians Outreach and Communication Activity) call this afternoon with their latest recommendations. \n\nDue to the high demand we anticipate for this COCA Call\, we kindly ask participants to access it in a group format\, if at all possible\, to allow for the maximum number of participants to attend. \nTarget audience: \n\nPhysicians\nNurses\nPharmacists\nVeterinarians\nPhysician Assistants\nHealth Educators\nOther Clinicians\n\nPlease note\, there will be only a few introductory slides for this presentation. The subject matter covered during this webinar will not have an accompanying slide deck. \n\nContact Information:coca@cdc.gov\nSupport/Funding:Centers for Disease Control and Prevention\, Emergency Risk Communication Branch\n\nPRESENTERS \nAron Hall\, DVM\, MSPH\n2019-nCoV Epidemiology Task Force Deputy Lead\nNational Center for Immunization and Respiratory Diseases\nCenters for Disease Control and Prevention \nWill Weldon\, PhD\n2019-nCoV Laboratory Task Force Lead\nNational Center for Immunization and Respiratory Diseases\nCenters for Disease Control and Prevention \nTimothy Uyeki\, MD\, MPH\, MPP\n2019-nCoV Response Clinical Team Lead\nNational Center for Immunization and Respiratory Diseases\nCenters for Disease Control and Prevention \nRyan Fagan\, MD\, MPH&TM\n2019-nCoV Healthcare Infection Control Team Lead\nNational Center for Emerging and Zoonotic Infectious Diseases\nCenters for Disease Control and Prevention \nPlease visit the website for call-in information
URL:https://globalbiodefense.com/event/cdc-coca-call-outbreak-of-2019-ncov-interim-guidance-for-clinicians/
CATEGORIES:Webinar-Webcast
END:VEVENT
END:VCALENDAR